We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+17.86%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$345M
AUM Growth
+$3.48M
Cap. Flow
-$46.4M
Cap. Flow %
-13.44%
Top 10 Hldgs %
30.53%
Holding
110
New
11
Increased
34
Reduced
36
Closed
26

Top Buys

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$13.9M
2
CELG
Celgene Corp
CELG
+$10.8M
3
RCPT
RECEPTOS INC COM STK (DE)
RCPT
+$5.32M
4
REGN icon
Regeneron Pharmaceuticals
REGN
+$3.74M
5
MDVN
MEDIVATION, INC.
MDVN
+$3.4M

Top Sells

Rank Stock Value
1
UHS icon
Universal Health Services
UHS
+$10.3M
2
MDT icon
Medtronic
MDT
+$6.86M
3
ALKS icon
Alkermes
ALKS
+$6.27M
4
INCY icon
Incyte
INCY
+$4.12M
5
NPSP
NPS PHARMACEUTICALS INC
NPSP
+$4.03M

Sector Composition

Rank Sector Weight
1 Healthcare 80.57%
2 Consumer Staples 1.97%
3 Financials 1.39%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MGNX icon
51
MacroGenics
MGNX
$257M
$2.63M 0.76%
75,000
-10,000
-12% -$249K
STJ
52
DELISTED
St Jude Medical
STJ
$2.6M 0.75%
40,000
-17,000
-30% -$1.09M
IONS icon
53
Ionis Pharmaceuticals
IONS
$9.4B
$2.59M 0.75%
42,000
-16,000
-28% -$790K
ARRY
54
DELISTED
Array Biopharma Inc
ARRY
$2.58M 0.75%
545,000
+165,801
+44% +$656K
AMSG
55
DELISTED
Amsurg Corp
AMSG
$2.57M 0.75%
47,000
+4,700
+11% +$240K
MDT icon
56
Medtronic
MDT
$112B
$2.53M 0.73%
35,000
-98,800
-74% -$6.86M
HOLX
57
DELISTED
Hologic
HOLX
$2.51M 0.73%
94,000
+4,000
+4% +$103K
AET
58
DELISTED
Aetna Inc
AET
$2.49M 0.72%
28,000
-7,000
-20% -$587K
CERN
59
DELISTED
Cerner Corp
CERN
$2.46M 0.71%
38,000
-2,000
-5% -$124K
EW icon
60
Edwards Lifesciences
EW
$51.7B
$2.42M 0.7%
114,000
-6,000
-5% -$121K
PODD icon
61
Insulet
PODD
$9.79B
$2.4M 0.69%
52,000
-10,911
-17% -$467K
TSRO
62
DELISTED
TESARO, Inc.
TSRO
$2.33M 0.68%
62,651
+7,651
+14% +$236K
ORI icon
63
Old Republic International
ORI
$10.4B
$2.32M 0.67%
+70,000
New +$1.02M
TNDM icon
64
Tandem Diabetes Care
TNDM
$1.56B
$2.27M 0.66%
+17,900
New +$2.48M
OREX
65
DELISTED
Orexigen Therapeutics, Inc.
OREX
$2.27M 0.66%
37,500
-11,900
-24% -$598K
PCYC
66
DELISTED
PHARMACYCLICS INC
PCYC
$2.26M 0.66%
18,500
-19,500
-51% -$2.49M
ALNY icon
67
Alnylam Pharmaceuticals
ALNY
$29.3B
$2.23M 0.65%
23,000
+9,970
+77% +$924K
CYBX
68
DELISTED
CYBERONICS INC
CYBX
$2.23M 0.65%
40,000
-3,000
-7% -$157K
RVNC
69
DELISTED
Revance Therapeutics, Inc.
RVNC
$2.14M 0.62%
126,574
+21,319
+20% +$372K
SUPN icon
70
Supernus Pharmaceuticals
SUPN
$2.77B
$2.08M 0.6%
250,800
+38,800
+18% +$326K
LGND icon
71
Ligand Pharmaceuticals
LGND
$6.36B
$2.08M 0.6%
62,517
– –
DVAX
72
DELISTED
Dynavax Technologies
DVAX
$2.07M 0.6%
122,835
– –
KITE
73
DELISTED
Kite Pharma, Inc.
KITE
$2.02M 0.58%
+35,000
New +$1.47M
OCR
74
DELISTED
OMNICARE INC
OCR
$1.82M 0.53%
25,000
+15,000
+150% +$1.02M
MYGN icon
75
Myriad Genetics
MYGN
$312M
$1.7M 0.49%
+50,000
New +$1.77M
1 2
3
4 5

Similar funds

PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return

Rhenman & Partners Asset Management's Q4 2014 Portfolio in Review

As of Q4 2014, Rhenman & Partners Asset Management held 110 positions worth $345M, up 1% from $342M the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Rhenman & Partners Asset Management withdrew a net $46.4M in Q4 2014, closing 26 positions and reducing 36 holdings. Its most notable exit was Universal Health Services, an estimated $10.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 81% of assets, up from 79% a quarter earlier, followed by Consumer Staples and Financials.

Against the trend, Rhenman & Partners Asset Management opened a new position in RECEPTOS INC COM STK (DE) worth $6.43M.

  • Rhenman & Partners Asset Management's largest Q4 2014 buy was RECEPTOS INC COM STK (DE): 52,526 shares worth $6.43M.
  • Rhenman & Partners Asset Management added most to Gilead Sciences in Q4 2014, an estimated $13.9M increase.
  • Rhenman & Partners Asset Management's biggest Q4 2014 reduction was Medtronic, cutting an estimated $6.86M.
  • Rhenman & Partners Asset Management fully exited Universal Health Services in Q4 2014, selling an estimated $10.3M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 31% of its $345M portfolio in Q4 2014.
  • Rhenman & Partners Asset Management opened 11 new positions and closed 26 in Q4 2014.
  • Rhenman & Partners Asset Management's portfolio value rose 1% quarter-over-quarter to $345M.

Based on Rhenman & Partners Asset Management's 13F filing for Q4 2014, filed 9 Feb 2015.